A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Item

http://www.wikidata.org/entity/Q37604531

Q37604531

about

Posttranslational Modifications and the Immunogenicity of Biotherapeutics Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example The changing landscape of biosimilars in rheumatology Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Latest therapeutic advances in musculoskeletal disease from the ACR 2015 annual conference.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.Biosimilars and the extrapolation of indications for inflammatory conditions.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Biosimilar biologic drugs: a new frontier in medical care.Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Clinical trials of biosimilars should become more similar.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psori Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.SB2: An Infliximab Biosimilar.Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab).Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.Biosimilars: Review of current applications, obstacles, and their future in medicine The biosimilars journey: current status and ongoing challenges

P2860

Q26748614-424DF69E-61EC-4A83-BB38-EFD209732F8C Q26766368-9824AB36-AFBA-49E5-BCF3-63A5CADECDC5 Q26766515-8CA29AD1-EFB8-44A0-BD38-2339B309941E Q28073310-B3EE0A61-71AB-4767-9B79-1A2885E8E489 Q28078423-AA481A3F-6DB5-4F5F-97BF-20AA6A97344B Q30397234-0C03DA82-7F3D-4D65-BDE8-68F68FDF7609 Q33881234-A6CB0784-1954-41ED-9BA4-78AFD61AAD9B Q36448681-3BF7C7AB-4F86-41EC-B07D-B72C85445CB5 Q38735477-DE15AE86-31D6-46BF-94DB-E5A52FB3BED4 Q38932150-839503F4-8A81-461C-B8CF-1CD7730A7B99 Q38977625-81FD7D14-A85B-4B6F-820E-256BA4A60ACE Q39200937-33E5B666-BD54-4D12-A4CE-10ECF4AEE611 Q42360803-004FF46D-FE01-42CD-B2C6-27B0BA8B2884 Q47688424-B529D307-3899-41C2-844D-16AA9906888F Q47731175-880DF3A2-6212-49C2-B9A0-95B8EFE6A108 Q47807650-DED7CF1E-D157-48E4-A353-EA3C293A34D9 Q48092147-9EE117E1-5CDA-4BC8-A714-44141F19199F Q50065301-86E030CA-A1F0-4463-9BCE-54A04E446F71 Q50073683-70E1A6C6-8DEC-41C5-9FA5-FAFA31FCD687 Q50079741-BC84D661-195A-456D-8247-37C652CA4B96 Q51359715-F485BCD5-84AD-4400-8B80-25131F4584BE Q52651099-FD5D9A59-148D-41E9-B1F3-6C309B23A232 Q53114131-47B892E5-696D-4229-B0B7-14785523EB55 Q54974248-3622F4EE-D894-4DD3-9784-B474FEE1C98E Q55008089-18D4EC0F-7BF4-4EA3-A6C4-A59112B3E1BB Q57169149-87FE3FBF-DC36-4B90-B0CD-8CA24E5D3CA0 Q57298628-8FD3BDFA-046E-4A54-979F-A91A08B1627F

P2860

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Item

http://www.wikidata.org/entity/Q37604531

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs